Researchers at the University of North Carolina have developed a novel immunotherapy that targets acute myeloid leukemia (AML) without harming healthy blood cells, addressing a major limitation of current treatments. The findings, published in the journal Blood, represent a significant step toward more precise and less toxic cancer therapies.
Led by immunologist Gianpietro Dotti and hematologist Paul Armistead, the research teams engineered immune cells capable of distinguishing between cancerous and normal cells. This selectivity is crucial because standard treatments for AML often destroy healthy blood tissue along with malignant cells, leading to severe side effects. The new approach could expand treatment options for patients with this aggressive form of blood cancer.
The study highlights the potential for advanced cancer therapies that minimize adverse effects. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also pursuing innovative immunotherapies, underscoring the growing interest in this field.
This research was supported by TinyGems, a communications platform focusing on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @IBN, which provides a range of services including wire solutions via InvestorWire, article syndication to over 5,000 outlets, and social media distribution. For more information about TinyGems and its services, visit https://www.TinyGems.com.
The UNC discovery could pave the way for immunotherapies that are both more effective and less harmful, offering hope to patients with limited options. Further studies are needed to translate these findings into clinical applications.
